Compare · AZN vs EQ
AZN vs EQ
Side-by-side comparison of AstraZeneca PLC (AZN) and Equillium Inc. (EQ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and EQ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 1903.3x EQ ($138.2M).
- AZN has been more active in the news (13 items in the past 4 weeks vs 4 for EQ).
- AZN has more recent analyst coverage (25 ratings vs 12 for EQ).
- Company
- AstraZeneca PLC
- Equillium Inc.
- Price
- -
- -
- Market cap
- $263.10B
- $138.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2018
- News (4w)
- 13
- 4
- Recent ratings
- 25
- 12
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Equillium Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
- SVP, Group Controller Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,267 units (SEC Form 4)
Latest EQ
- SEC Form 10-Q filed by Equillium Inc.
- Equillium Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
- Amendment: SEC Form SCHEDULE 13G/A filed by Equillium Inc.
- Piper Sandler initiated coverage on Equillium
- Sr. Vice President and COO Zedelmayer Christine exercised 14,584 shares at a strike of $0.79 and sold $42,737 worth of shares (14,584 units at $2.93) as part of a pre-agreed trading plan (SEC Form 4)
- President and CSO Connelly Stephen sold $723,830 worth of shares (230,975 units at $3.13), decreasing direct ownership by 23% to 762,025 units (SEC Form 4)
- Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Principal Accounting Officer Tom Penny sold $191,750 worth of shares (65,000 units at $2.95) as part of a pre-agreed trading plan and exercised 65,000 shares at a strike of $0.79 (SEC Form 4)
- SEC Form 4 filed by Director Demski Martha J